SLC5A2 and Mitral regurgitation: Additionally, treatment strategies such as beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, along with risk factors like valvular heart disease, mitral regurgitation, and cardiomyopathy in pregnancy, demonstrated high APY(around 2022).